Today: 20 May 2026
GE Vernova stock price today: GEV slips as $2.6B bond deal closes, wind repower update back in view
5 February 2026
2 mins read

GE Vernova stock price today: GEV slips as $2.6B bond deal closes, wind repower update back in view

New York, February 5, 2026, 11:59 (EST) — Regular session

  • Shares of GE Vernova dropped roughly 1.6% in late-morning trading
  • The company wrapped up a $2.6 billion senior notes offering to finance its acquisition of Prolec GE.
  • The wind unit flagged 1.1 GW of U.S. repower orders lined up for 2025; Baird responded by upgrading the stock

Shares of GE Vernova Inc. fell roughly 1.6% to $734.33 in late-morning trading on Thursday. Earlier in the session, the stock fluctuated between $712.09 and $762.39.

Utilities are racing to boost generation and upgrade grid equipment as data center power demand surges. On Thursday, Xcel Energy posted a 22% rise in quarterly profit and revealed it struck deals with NextEra Energy and GE Vernova earlier this week to accelerate electricity output.

GE Vernova revealed in a filing that it has wrapped up an underwritten $2.6 billion senior notes offering, with maturities set for 2031, 2036, and 2056. The bonds feature coupons at 4.250%, 4.875%, and 5.500%. The company intends to use the proceeds for general corporate purposes, including funding part of its recent acquisition of the remaining 50% stake in Prolec GE, finalized on Feb. 2. Citigroup, J.P. Morgan, and Morgan Stanley led the underwriting, according to the filing.

GE Vernova reported securing orders in 2025 to repower 1.1 gigawatts of U.S. onshore turbines, upgrading older units with updated nacelles and drive trains from its Pensacola, Florida plant. Uzair Memon, chief commercial officer for onshore wind services, described the orders as proof of “the critical role our advanced technology plays.” Wind executive David Hardy added that repowering can “rejuvenate a wind farm” and cut operations and maintenance costs. The company expects these projects to be commercially operational between 2026 and 2027. GE Vernova also clarified this announcement does not include new orders beyond what was previously disclosed. businesswire.com

Xcel has finalized a reservation agreement to purchase five F-class gas turbines from GE Vernova and secured capacity reservations for several gigawatts of wind projects using GE’s turbines—locking in future production slots. GE Vernova CEO Scott Strazik said the deal allows both companies to “align our technology roadmaps.” Xcel CEO Bob Frenzel added the partnership is designed to help them move “at the speed and scale” needed to meet demand. newsroom.xcelenergy.com

Analyst sentiment has turned. On Wednesday, Baird upgraded GE Vernova to Outperform, boosting its price target from $701 to $923. Analyst Ben Kallo said concerns overcapacity are “farther away” than previously thought and pointed to GE Vernova as a potential “biggest beneficiary” of the energy-infrastructure cycle. investing.com

Traders are focused on whether customer reservations and service work are turning into higher-margin revenue fast enough to counter rising financing costs and maintain cash flow. The debt raise and the wind-services news provide some support for the bigger picture, but neither offers a clear “new orders today” boost.

But the trade-off runs both ways. More debt means tougher execution hurdles, and investors quickly shrug off press releases that either recycle old order numbers or delay cash flow projections.

GE Vernova will hold its first-quarter 2026 earnings webcast on April 22. Investors will be watching closely for updates on new order intake, free cash flow, and any revisions to the 2026 guidance.

Stock Market Today

  • Roivant Sciences Q4 Loss Beats Estimates; Revenue Misses
    May 20, 2026, 9:59 AM EDT. Roivant Sciences Ltd. reported a fourth-quarter loss of $0.23 per share, better than the Zacks estimate of a $0.25 loss, marking an 8% positive earnings surprise. Revenue missed expectations, coming in at $28.93 million, down 11% from estimates but up from $27.38 million a year ago. Despite three out of four quarters beating EPS estimates recently, the company's shares have declined 4.5% year-to-date, underperforming the S&P 500's 10.4% rise. Earnings outlook remains cautious with a Zacks Rank #4 (Sell), suggesting expected near-term underperformance. Current consensus projects a loss of $0.21 per share next quarter on $56.64 million revenue and a fiscal year loss of $1.07 on $172.45 million. Industry outlook in medical-biomedical genetics also weighs on investor sentiment.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
AppLovin stock extends slide as CloudX worries hang over ad-tech ahead of earnings
Previous Story

AppLovin stock extends slide as CloudX worries hang over ad-tech ahead of earnings

Applied Materials (AMAT) stock snaps back near $300 as Alphabet AI spend stirs chip-equipment trade
Next Story

Applied Materials (AMAT) stock snaps back near $300 as Alphabet AI spend stirs chip-equipment trade

Go toTop